selected publications
- How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease. Clinical parkinsonism & related disorders. 2025 Review GET IT
-
Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
Movement disorders : official journal of the Movement Disorder Society.
2023
Academic Article
GET IT
Times cited: 5 -
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.
JAMA neurology.
2023
Academic Article
GET IT
Times cited: 25 -
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey.
Parkinson's disease.
2021
Academic Article
GET IT
Times cited: 3 -
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Parkinsonism & related disorders.
2020
Academic Article
GET IT
Times cited: 5 -
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Journal of Parkinson's disease.
2020
Academic Article
GET IT
Times cited: 3